Viktor Syzonenko > Arzinger > Kiev, Ukraine > Lawyer Profile
SENATOR BUSINESS CENTRE
32/2 MOSKOVSKA STREET, 10TH FLOOR
- Go to...
Head of South Ukrainian Branch, Attorney-At-Law
Prior to joining Arzinger team, Viktor worked in different positions, both as in-house and in consulting. He has experience in such systemically important banks as PUMB and Oschadbank. In recent years, he has been focused on working with IT business both as Head of Legal Function and as a manager of a product company.
Since May 2019 Viktor heads the South Ukrainian Branch of Arzinger in Odesa. Lawyers of the Branch are engaged in a number of large-scale projects, including in real estate consulting, construction, information technology, business structuring, litigation representation, consulting and support for PPP projects, concessions, investing in strategic port infrastructure, etc. Arzinger Branch in Odessa aims at taking the first place among the leading regional law firms in the Southern region of Ukraine.
English, Russian, Ukrainian
- Union of Ukrainian Entrepreneurs (SUP)
- South Ukrainian Office of the European Business Association (EBA)
- American Chamber of Commerce in Ukraine (ACC)
- German-Ukrainian Chamber of Industry and Commerce (AHK Ukraine)
- Ukrainian Advocates’ Association
- Ukrainian Bar Association
Chicago-Kent College of Law, LL.M., U.S., International & Transnational Law
Donetsk Law Institute, Master of Law
Arzinger has a real estate and construction practice that operates from three offices in Ukraine, all of which handle high-value sales and leasing matters. The practice is jointly led by Timur Bondaryev in Kiev, Markian Malskyy in Lviv and Viktor Syzonenko in Odessa. They frequently act for international and Ukrainian public and private companies, financial institutions and funds. The team’s experience spans residential, commercial, infrastructure, and industrial projects, as well as handling real estate issues arising from large M&A transactions. The firm recently assisted STADA Arzneimittel with real estate aspects of the purchase of a pharmaceuticals company.